MEK-话题@MedSci - williamhill asia

#MEK#

68篇内容 | 1584人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1943937, encodeId=3a5b194393e71, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Neuro-Oncology：用于1型神经纤维瘤病的MEK抑制剂的临床证据和共识, objectType=article, longId=732817, objectId=fd3ce32817fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd3ce32817fa, replyNumber=0, likeNumber=119, createdTime=2023-06-10, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd3ce32817fa, moduleTitle=Neuro-Oncology：用于1型神经纤维瘤病的MEK抑制剂的临床证据和共识, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=fd3ce32817fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943936, encodeId=153919439363d, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤, objectType=article, longId=731840, objectId=fa30e31840a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa30e31840a0, replyNumber=0, likeNumber=92, createdTime=2023-02-09, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa30e31840a0, moduleTitle=J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=fa30e31840a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943930, encodeId=eacd194393022, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=NEJM：Bimekizumab VS. Secukinumab 治疗斑块状银屑病的疗效及安全性, objectType=article, longId=218429, objectId=869b2184298f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=869b2184298f, replyNumber=0, likeNumber=78, createdTime=2021-11-10, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=869b2184298f, moduleTitle=NEJM：Bimekizumab VS. Secukinumab 治疗斑块状银屑病的疗效及安全性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=869b2184298f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943931, encodeId=de641943931f8, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差, objectType=article, longId=218646, objectId=e1fc218646bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1fc218646bf, replyNumber=0, likeNumber=64, createdTime=2022-01-28, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1fc218646bf, moduleTitle=J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e1fc218646bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943934, encodeId=dba71943934e2, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=J Clin Oncol：采用MEK抑制剂Selumetinib治疗携带MAPK通路变异的恶性肿瘤, objectType=article, longId=724283, objectId=8cc1e24283bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8cc1e24283bf, replyNumber=0, likeNumber=61, createdTime=2022-06-05, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8cc1e24283bf, moduleTitle=J Clin Oncol：采用MEK抑制剂Selumetinib治疗携带MAPK通路变异的恶性肿瘤, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=8cc1e24283bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943933, encodeId=f5fd194393392, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效, objectType=article, longId=300803, objectId=cb143008036b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb143008036b, replyNumber=0, likeNumber=85, createdTime=2022-10-10, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb143008036b, moduleTitle=Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=cb143008036b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943929, encodeId=f6c3194392919, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=NEJM：Bimekizumab与阿达木单抗对斑块状银屑病的疗效比较，王者诞生？, objectType=article, longId=213912, objectId=0cae21391291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cae21391291, replyNumber=0, likeNumber=59, createdTime=2022-03-11, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cae21391291, moduleTitle=NEJM：Bimekizumab与阿达木单抗对斑块状银屑病的疗效比较，王者诞生？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0cae21391291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943932, encodeId=7a461943932e8, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=J Clin Invest：MEK抑制剂 cobimetinib联合PD-L1抑制剂 atezolizumab可延长胆道癌(BTC)的PFS, objectType=article, longId=293561, objectId=cf2c293561b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf2c293561b4, replyNumber=0, likeNumber=71, createdTime=2022-11-22, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf2c293561b4, moduleTitle=J Clin Invest：MEK抑制剂 cobimetinib联合PD-L1抑制剂 atezolizumab可延长胆道癌(BTC)的PFS, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=cf2c293561b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943928, encodeId=7dbe1943928d7, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=NEJM：白介素17A/17F双重抑制剂Bimekizumab治疗中重度斑块性银屑病, objectType=article, longId=210420, objectId=5536210420a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5536210420a0, replyNumber=0, likeNumber=115, createdTime=2022-03-10, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5536210420a0, moduleTitle=NEJM：白介素17A/17F双重抑制剂Bimekizumab治疗中重度斑块性银屑病, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5536210420a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943923, encodeId=a13b194392397, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Br J Cancer：倾向匹配生存分析揭示在携带BRAFV600突变的晚期黑色素瘤患者中抗PD-1单药治疗优于BRAF/MEK抑制剂治疗, objectType=article, longId=206683, objectId=000c20668335, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=000c20668335, replyNumber=0, likeNumber=84, createdTime=2021-03-10, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=000c20668335, moduleTitle=Br J Cancer：倾向匹配生存分析揭示在携带BRAFV600突变的晚期黑色素瘤患者中抗PD-1单药治疗优于BRAF/MEK抑制剂治疗, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=000c20668335)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943922, encodeId=6d7d194392255, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Eur J Cancer：BRAF和MEK抑制剂联合治疗亚洲晚期黑色素瘤患者的疗效, objectType=article, longId=206376, objectId=d9952063e6c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9952063e6c2, replyNumber=0, likeNumber=63, createdTime=2021-03-01, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9952063e6c2, moduleTitle=Eur J Cancer：BRAF和MEK抑制剂联合治疗亚洲晚期黑色素瘤患者的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d9952063e6c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943926, encodeId=ddee19439265e, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Neuro Oncol：MEK-1/2抑制剂selumetinib明显改善复发性/进展性儿童低级别胶质瘤预后, objectType=article, longId=207690, objectId=df0620e690db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df0620e690db, replyNumber=0, likeNumber=60, createdTime=2021-12-15, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df0620e690db, moduleTitle=Neuro Oncol：MEK-1/2抑制剂selumetinib明显改善复发性/进展性儿童低级别胶质瘤预后, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=df0620e690db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943920, encodeId=d6281943920fd, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Nat Immunol ：抑制MEK可将CD8+T细胞重编程为抗肿瘤型记忆干细胞, objectType=article, longId=203915, objectId=7c2b203915cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c2b203915cd, replyNumber=0, likeNumber=72, createdTime=2021-05-21, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c2b203915cd, moduleTitle=Nat Immunol ：抑制MEK可将CD8+T细胞重编程为抗肿瘤型记忆干细胞, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=7c2b203915cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943927, encodeId=2a49194392e98, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=NEJM：Bimekizumab vs 阿达木单抗治疗中重度斑块性银屑病, objectType=article, longId=210416, objectId=17a3210416be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17a3210416be, replyNumber=0, likeNumber=46, createdTime=2021-05-20, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17a3210416be, moduleTitle=NEJM：Bimekizumab vs 阿达木单抗治疗中重度斑块性银屑病, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=17a3210416be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943916, encodeId=07a81943916e7, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=FDA和EMA已接受bimekizumab治疗银屑病的市场营销申请, objectType=article, longId=201331, objectId=04f220133102, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04f220133102, replyNumber=0, likeNumber=65, createdTime=2021-01-29, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04f220133102, moduleTitle=FDA和EMA已接受bimekizumab治疗银屑病的市场营销申请, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=04f220133102)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943913, encodeId=d26419439131e, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, objectType=article, longId=195839, objectId=0f4c19583900, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f4c19583900, replyNumber=0, likeNumber=51, createdTime=2020-08-08, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f4c19583900, moduleTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0f4c19583900)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943918, encodeId=69c41943918f3, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Lancet oncol：RAF-MEK抑制剂在携带RAS/RAF突变的多种肿瘤中的抗肿瘤活性, objectType=article, longId=202766, objectId=2fe5202e6622, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fe5202e6622, replyNumber=0, likeNumber=70, createdTime=2021-06-30, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fe5202e6622, moduleTitle=Lancet oncol：RAF-MEK抑制剂在携带RAS/RAF突变的多种肿瘤中的抗肿瘤活性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=2fe5202e6622)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943912, encodeId=0c3519439128b, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=J Periodontal Res：LncRNA-01126通过MEK/ERK信号通路抑制人牙周膜细胞的迁移, objectType=article, longId=194677, objectId=b08b1946e719, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b08b1946e719, replyNumber=0, likeNumber=62, createdTime=2020-08-01, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b08b1946e719, moduleTitle=J Periodontal Res：LncRNA-01126通过MEK/ERK信号通路抑制人牙周膜细胞的迁移, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b08b1946e719)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943935, encodeId=6cdd1943935c6, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=Clin Cancer Res：抗疟疾药氯喹可增加GNAQ/11突变性黑色素瘤对MEK1/2抑制剂的敏感性！, objectType=article, longId=200796, objectId=d03f200e96fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d03f200e96fe, replyNumber=0, likeNumber=87, createdTime=2021-02-10, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d03f200e96fe, moduleTitle=Clin Cancer Res：抗疟疾药氯喹可增加GNAQ/11突变性黑色素瘤对MEK1/2抑制剂的敏感性！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d03f200e96fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943925, encodeId=066119439258f, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, objectTitle=UCB在《Lancet》上发表bimekizumab治疗斑块状银屑病的全新数据, objectType=article, longId=206929, objectId=119120692979, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=119120692979, replyNumber=0, likeNumber=55, createdTime=2021-09-18, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=119120692979, moduleTitle=UCB在《Lancet》上发表bimekizumab治疗斑块状银屑病的全新数据, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=119120692979)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

MEK

2020-05-29

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Neuro-Oncology：用于1型神经纤维瘤病的MEK抑制剂的临床证据和共识

2023-06-10

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

J Immunother Cancer：抗PD1±抗CTLA4治疗BRAF/MEK抑制剂治疗失败的V600BRAF突变型转移性黑色素瘤

2023-02-09

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

NEJM：Bimekizumab VS. Secukinumab 治疗斑块状银屑病的疗效及安全性

2021-11-10

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差

2022-01-28

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

J Clin Oncol：采用MEK抑制剂Selumetinib治疗携带MAPK通路变异的恶性肿瘤

2022-06-05

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效

2022-10-10

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

NEJM：Bimekizumab与阿达木单抗对斑块状银屑病的疗效比较，王者诞生？

2022-03-11

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

J Clin Invest：MEK抑制剂 cobimetinib联合PD-L1抑制剂 atezolizumab可延长胆道癌(BTC)的PFS

2022-11-22

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

NEJM：白介素17A/17F双重抑制剂Bimekizumab治疗中重度斑块性银屑病

2022-03-10

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Br J Cancer：倾向匹配生存分析揭示在携带BRAFV600突变的晚期黑色素瘤患者中抗PD-1单药治疗优于BRAF/MEK抑制剂治疗

2021-03-10

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Eur J Cancer：BRAF和MEK抑制剂联合治疗亚洲晚期黑色素瘤患者的疗效

2021-03-01

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Neuro Oncol：MEK-1/2抑制剂selumetinib明显改善复发性/进展性儿童低级别胶质瘤预后

2021-12-15

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Nat Immunol ：抑制MEK可将CD8+T细胞重编程为抗肿瘤型记忆干细胞

2021-05-21

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

NEJM：Bimekizumab vs 阿达木单抗治疗中重度斑块性银屑病

2021-05-20

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

FDA和EMA已接受bimekizumab治疗银屑病的市场营销申请

2021-01-29

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab

2020-08-08

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Lancet oncol：RAF-MEK抑制剂在携带RAS/RAF突变的多种肿瘤中的抗肿瘤活性

2021-06-30

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

J Periodontal Res：LncRNA-01126通过MEK/ERK信号通路抑制人牙周膜细胞的迁移

2020-08-01

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

Clin Cancer Res：抗疟疾药氯喹可增加GNAQ/11突变性黑色素瘤对MEK1/2抑制剂的敏感性！

2021-02-10

naiwu77 (审核中...)

前往app查看评论内容

#MEK#

UCB在《Lancet》上发表bimekizumab治疗斑块状银屑病的全新数据

2021-09-18

科室
- - 订阅+
  - 更多科室
工具
服务